Bristol-Myers Squibb Company PFD CONV 2
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis… Read more
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) - Total Liabilities
Latest total liabilities as of September 2024: $76.47 Billion USD
Based on the latest financial reports, Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) has total liabilities worth $76.47 Billion USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bristol-Myers Squibb Company PFD CONV 2 - Total Liabilities Trend (1987–2023)
This chart illustrates how Bristol-Myers Squibb Company PFD CONV 2's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bristol-Myers Squibb Company PFD CONV 2 Competitors by Total Liabilities
The table below lists competitors of Bristol-Myers Squibb Company PFD CONV 2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wing Yip Food (China) Holdings Group Limited
KQ:900340
|
Korea | ₩42.79 Million |
|
PCF Group SA
WAR:PCF
|
Poland | zł107.73 Million |
|
GTL Limited
NSE:GTL
|
India | ₹62.02 Billion |
|
A1 Investments & Resources Ltd
AU:AYI
|
Australia | AU$317.73K |
|
Farminveste, S.G.P.S., S.A.
LS:MLFMV
|
Portugal | €448.75 Million |
|
Venus Metals Corporation Ltd
AU:VMC
|
Australia | AU$353.13K |
|
Q Capital Partners Co. Ltd
KQ:016600
|
Korea | ₩44.56 Billion |
Liability Composition Analysis (1987–2023)
This chart breaks down Bristol-Myers Squibb Company PFD CONV 2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.82 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bristol-Myers Squibb Company PFD CONV 2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bristol-Myers Squibb Company PFD CONV 2 (1987–2023)
The table below shows the annual total liabilities of Bristol-Myers Squibb Company PFD CONV 2 from 1987 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $65.67 Billion | -0.04% |
| 2022-12-31 | $65.70 Billion | -10.38% |
| 2021-12-31 | $73.31 Billion | -9.05% |
| 2020-12-31 | $80.60 Billion | +3.01% |
| 2019-12-31 | $78.25 Billion | +964.72% |
| 2018-12-31 | $7.35 Billion | -66.14% |
| 2017-12-31 | $21.70 Billion | +25.02% |
| 2016-12-31 | $17.36 Billion | +0.21% |
| 2015-12-31 | $17.32 Billion | -7.68% |
| 2014-12-31 | $18.77 Billion | -19.65% |
| 2013-12-31 | $23.36 Billion | +4.93% |
| 2012-12-31 | $22.26 Billion | +30.15% |
| 2011-12-31 | $17.10 Billion | +10.79% |
| 2010-12-31 | $15.44 Billion | -4.84% |
| 2009-12-31 | $16.22 Billion | -6.29% |
| 2008-12-31 | $17.31 Billion | +10.90% |
| 2007-12-31 | $15.61 Billion | +0.17% |
| 2006-12-31 | $15.58 Billion | -7.95% |
| 2005-12-31 | $16.93 Billion | -16.32% |
| 2004-12-31 | $20.23 Billion | +14.41% |
| 2003-12-31 | $17.68 Billion | +11.18% |
| 2002-12-31 | $15.91 Billion | -2.54% |
| 2001-12-31 | $16.32 Billion | +94.34% |
| 2000-12-31 | $8.40 Billion | -0.84% |
| 1999-12-31 | $8.47 Billion | -2.61% |
| 1998-12-31 | $8.70 Billion | +12.09% |
| 1997-12-31 | $7.76 Billion | -4.40% |
| 1996-12-31 | $8.12 Billion | +0.10% |
| 1995-12-31 | $8.11 Billion | +12.50% |
| 1994-12-31 | $7.21 Billion | +16.96% |
| 1993-12-31 | $6.16 Billion | +28.78% |
| 1992-12-31 | $4.78 Billion | +32.12% |
| 1991-12-31 | $3.62 Billion | -4.64% |
| 1990-12-31 | $3.80 Billion | +11.25% |
| 1989-12-31 | $3.41 Billion | +2.65% |
| 1988-12-31 | $3.33 Billion | +20.51% |
| 1987-12-31 | $2.76 Billion | -- |